Pure Global AI
NCT06319703Not yet recruiting

Implementing an Effective Diabetes Intervention Among Low-Income Immigrants

IDEAL: Implementing an Effective Diabetes intervEntion Among Low-income Immigrants
NYU Langone HealthClinicalTrials.govbehavioral
Verified
Study focus
Disease/Condition
Type 2 Diabetes
Drug/Device/Intervention
Diabetes Self-Management Education and Support (DSMES) Videos
Study type
Interventional
Intervention type
behavioral
Sponsor & location
Primary sponsor
NYU Langone Health
Location
New York, United States of America
Timeline & enrollment
Phase
N/A
Start date
May 01, 2024
End date
Mar 31, 2028
Enrollment
270 participants
Primary outcome

Change in Hemoglobin A1C (HbA1c) Test Scores,Change in Hemoglobin A1C (HbA1c) Test Scores

Summary

The goal of this IDEAL project is to examine the effectiveness and implementation process of
 the video-based Diabetes Self-Management Education and Support (DSMES) + community health
 worker (CHW) (hereafter: IDEAL) intervention compared with a wait-list control group
 (hereafter: CONTROL) to improve glycemic control among Chinese immigrants with Type 2
 diabetes (T2D) in New York City (NYC). Participants will be randomized with equal allocation
 to one of the 2 groups. The IDEAL group will receive 1 DSMES brief video/week for 24 weeks
 delivered via text message. The CHW will assess participants' SDOH barriers to T2D care and
 link them to available resources in the community. The CONTROL group will continue to receive
 their usual care and at the end of the study, they will receive DSMES videos.

ICD-10 classifications
Type 2 diabetes mellitusType 2 diabetes mellitus without complicationsType 2 diabetes mellitus with unspecified complicationsType 2 diabetes mellitus with other specified complicationsType 2 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06319703
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06319703 through Pure Global AI's free database. This phase not specified trial is sponsored by NYU Langone Health and is currently Not yet recruiting. The study focuses on Type 2 Diabetes. Target enrollment is 270 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.